UK EXECUTIVE CHANGE SUMMARY: 65-Year Stint At Heavitree Brewery Ends
UK EXECUTIVE CHANGE SUMMARY: 65-Year Stint At Heavitree Brewery Ends
Read moreUK EXECUTIVE CHANGE SUMMARY: 65-Year Stint At Heavitree Brewery Ends
Read more(Sharecast News) - Analysts at Liberum raised their target price on biotechnology company PureTech Health from 450.0p to 490.0p on Wednesday, stating the firm had made some "underappreciated" progress.
Read more(Sharecast News) - Sanne: RBC Capital Markets reiterates sector performer with a target price of 600.0p.
Read more(Sharecast News) - The Sunday Times's Sabah Meddings told readers of her 'Inside the City' column to 'buy' shares of PureTech, citing the the drug maker's ingenious 'portfolio' approach and ample pipeline of treatments in various phases of development.
Read moreIN BRIEF: PureTech's Sonde Launches Virus Safe Voice Sample Health App
Read more(Sharecast News) - Analysts at Peel Hunt reiterated their 'Conviction Buy' recommendation for shares of PureTech Health following a $110.0m funding round for its founded entity Vor Biopharma, arguing that the transaction validated its business model.
Read moreUK TRADING UPDATE SUMMARY: Retailer Sosandar In Quarterly Revenue Jump
Read more(Sharecast News) - Biotherapeutics company PureTech Health said its founded entity Akili had received a CE-mark for 'EndeavorRx treatment for attention deficit hyperactivity disorder (ADHD).
Read moreIN BRIEF: Puretech Health Partners With China Medical System
Read moreIN BRIEF: PureTech's Akili In Green Light For Video Game ADHD Therapy
Read more(Sharecast News) - Clinical-stage biotherapeutics company PureTech Health announced on Tuesday that its subsidiary Akili has been granted US Food and Drug Administration (FDA) clearance for 'EndeavorRx', or AKL-T01, as a prescription treatment for children with attention deficit hyperactivity disorder (ADHD).
Read moreUK TRADING UPDATE SUMMARY: Venture Life Sees Order Boost For Sanitiser
Read more(Sharecast News) - Clinical-stage biotherapeutics company PureTech Health reported some "positive" topline data from two Phase 1 studies into VE202, its orally-administered inflammatory bowel disease treatment candidate.
Read moreUK TRADING UPDATE SUMMARY: Open Orphan Launches Covid Testing Service
Read moreUK TRADING UPDATE SUMMARY: Novacyt Virus Test Orders At EUR135 Million
Read more